Chinese Journal of Pharmacovigilance ›› 2018, Vol. 15 ›› Issue (8): 499-500.
Previous Articles Next Articles
WANG Ying, CUI Xiangli*, LIU Lihong
Received:2018-10-11
Revised:2018-10-11
Online:2018-08-20
Published:2018-10-11
CLC Number:
WANG Ying, CUI Xiangli, LIU Lihong. One Case of Mental Abnormality Induced by Drug Interaction[J]. Chinese Journal of Pharmacovigilance, 2018, 15(8): 499-500.
Add to citation manager EndNote|Ris|BibTeX
| [1] 赵晶,周颖,崔一民,等. 129例伏立康唑致精神症状不良反应分析[J]. 临床药物治疗杂志,2016,14(4):67-71. [2] 陈美兰,童秀珍,李娟,等. 伏立康唑引起精神症状6例临床分析[J]. 中国神经精神疾病杂志, 2014,40(8):483-485. [3] 胡琴,刘维,邵宏. 伏立康唑联用糖皮质激素致谵妄1例[J]. 药品评价, 2015,12(10):41-44. [4] Pascual A, Calandra T, Bolay S, et al.Voriconazoletherapeutic drug monitoring in patients with invasive mycoses improves efficacyand safety outcomes[J]. Clin Infect Dis, 2008,46(2):201-211. [5] Boyd A E, Modi S, Howard S J, et al.Adverse reactionsto voriconazole[J]. Clin Infect Dis, 2004,39(8):1241-1244. [6] 杨海,赵海. 奥美拉唑诱发精神异常1例[J]. 中国药物警戒, 2012,9(10):639. [7] 刘波,姚鸿萍. 临床常用质子泵抑制剂的研究进展[J]. 西北药学杂志, 2014,29(3):328-332. [8] Yang H X, Chen K, Liang S Y, et al.Effect of cytochrome P-450 inhibitors on pharmacokinetics and safety of voriconazole[J]. J Chin Pharm Sci, 2017,26(3),202-211. [9] 付丽芳,赖善城. 药物引起神经精神症状不良反应文献统计分析[J].西藏医药杂志, 2011,3(4):52-53. [10] 钟古华,廖君兰,廖小凤,等. 糖皮质激素导致精神症状影响因素分析[J]. 国际精神病学杂志, 2016,43(5),809-812. [11] 万志龙,刘明亮. 莫西沙星的安全性评价[J]. 国外医药抗生素分册, 2006,27(3):105-109. |
| [1] | LI Xinying, BAO Lei, LI Shuran, ZHAO Ronghua, SUN Jing, XIE Dan, BAO Yanyan, GUO Shanshan, CUI Xiaolan, GENG Zihan. Effect of Shufeng Jiedu Capsules on the Production of Specific Antibodies against Influenza A H1N1 Virus and the Mechanisms [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 841-850. |
| [2] | WANG Xinwei, PENG Yifeng, SUN Jing, JI Zuen, BAO Lei, LUO Henglei, GENG Zihan, ZHANG Hujuan, LI Shuran, ZHANG Jingsheng, GUO Shanshan, CUI Xiaolan, ZHAO Ronghua. Effect of Yiye Anti-Influenza Capsules on Pneumonia Induced by Human Coronavirus 229E Infection in Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 851-855. |
| [3] | XIE Rui, SUN Qiyue, LI Yanying, ZHANG Jingsheng, ZHAO Ronghua, GUO Shanshan, GENG Zihan, BAO Lei, GAO Shuangrong, CUI Xiaolan, XIE Dan, SUN Jing. Impacts of Shuangshenling Granules on a Cadmium-Induced Chronic Renal Failure Model of Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 856-862. |
| [4] | CHEN Siying, DING Xueli, LIU Shujia, ZHANG Xiaomeng, ZHANG Bing, LIN Zhijian. Modeling for Prediction of Cardiotoxicity of Chinese Herbal Medicines [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 869-875. |
| [5] | CAI Haili, ZHANG Xiaomeng, LIU Yadi, CHEN Lijuan, WANG Yu, ZHANG Bing. Preventive Strategies for Anthracycline-Induced Cardiotoxicity Using Traditional Chinese Medicine via Ferroptosis Regulation [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 876-882. |
| [6] | ZHENG Haiyun, WANG Zhigang, WU Hongwei, WANG Shaonan, WANG Bin. Identification of in vitro and in vivo Chemical Constituents of Buxin Anmian Decoction Based on UPLC-Q Exactive Orbitrap HRMS [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 883-888. |
| [7] | SUN Ya, WANG Xu, SUN Zhi, ZHOU Yubing. Dose Analysis of Linezolid in Severe Patients with Sepsis Complicated with Acute Kidney Injury [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 889-895. |
| [8] | SHI Qi, WANG Jianxin, WANG Guijie, LU Yueyang, ZHU Jiaxu, GAO Rui. Adjuvant Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease with Qingqi Huatan Pills: a Systematic Review [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 914-919. |
| [9] | YING Jie, XU Xiaolong, LI Bo, LIU Tengwen, LIU Qingquan. Clinical Applications of Jinhua Qinggan Granules in the Treatment of Mild Influenza: a Meta-Analysis [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 920-923. |
| [10] | KE Xiuqin, HAI Xuewu. 433 Cases of Adverse Drug Reactions Induced by Calcium Dobesilate Capsules [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 924-927. |
| [11] | LIANG Jie. 172 Cases of Adverse Drug Reactions Induced by Antineoplastic Drugs [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 928-932. |
| [12] | LIU Jiang, CHEN Jie, QIU Sihong, LI Na, ZHOU Ying, CHEN Yonggang, LUO Ji. Analysis of Adverse Drug Event Induced by Omacycline and Moxifloxacin Based on FAERS Databse [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 933-936. |
| [13] | ZHAO Mudan, ZHU Minghui, ZHANG Huan, ZHAO Yuanyang, QIN Jing. Pharmaceutical Care of a Case of Diabetic Foot Infection Caused by Proteus penneri [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 937-940. |
| [14] | ZHOU Yujie, HUANG Xiaojing, CHEN Mingyue, DU Pengqiang, WANG Aifeng. Two Cases of Severe Thrombocytopenia Caused by Cefoperazone Sulbactam Sodium [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 941-943. |
| [15] | CHEN Huabao, LIU Wei, JIANG Ting, ZHENG Lingli, LI Jing. One Case of Acute Withdrawal Syndrome Caused by Naloxone [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 944-946. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
